MNPR vs. CDTX

Last updated Apr 1, 2026

Compare and contrast key facts about Monopar Therapeutics Inc. (MNPR) and Cidara Therapeutics, Inc. (CDTX).

Performance

MNPR vs. CDTX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Monopar Therapeutics Inc. (MNPR) and Cidara Therapeutics, Inc. (CDTX). The values are adjusted to include any dividend payments, if applicable.

MNPR vs. CDTX - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019
MNPR Monopar Therapeutics Inc.	-16.09%	196.82%	1,193.36%	-85.65%	-26.17%	-47.55%	-63.13%	-37.36%
CDTX Cidara Therapeutics, Inc.	0.22%	721.76%	69.27%	4.98%	-40.45%	-36.50%	-47.92%	60.67%

Fundamentals

EPS MNPR : -$2.75 CDTX : -$11.88
Total Revenue (TTM) MNPR : $0.00 CDTX : $0.00
Gross Profit (TTM) MNPR : $0.00 CDTX : -$45.00M
EBITDA (TTM) MNPR : -$20.04M CDTX : -$189.91M

Returns By Period

MNPR

• 1D: 2.81%
• 1M: -0.03%
• YTD: -16.09%
• 6M: -32.91%
• 1Y: 50.48%
• 3Y*: 99.02%
• 5Y*: 11.99%
• 10Y*: —

CDTX

• 1D: —
• 1M: —
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

MNPR vs. CDTX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

MNPR

MNPR Risk / Return Rank: 61
MNPR Sharpe Ratio Rank: 63
MNPR Sortino Ratio Rank: 67
MNPR Omega Ratio Rank: 62
MNPR Calmar Ratio Rank: 59
MNPR Martin Ratio Rank: 56

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

MNPR vs. CDTX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Monopar Therapeutics Inc. (MNPR) and Cidara Therapeutics, Inc. (CDTX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	MNPR	CDTX	Difference
Sharpe ratio Return per unit of total volatility	0.59	—	—
Sortino ratio Return per unit of downside risk	1.44	—	—
Omega ratio Gain probability vs. loss probability	1.17	—	—
Calmar ratio Return relative to maximum drawdown	0.73	—	—
Martin ratio Return relative to average drawdown	1.36	—	—
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

Sharpe Ratios by Period

	MNPR	CDTX	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.59	—	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.04	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.05	—	—

Correlation

The correlation between MNPR and CDTX is 0.11, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

MNPR vs. CDTX - Dividend Comparison

Neither MNPR nor CDTX has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

Drawdown Indicators

	MNPR	CDTX	Difference
Max Drawdown Largest peak-to-trough decline	-98.93%	—	—
Max Drawdown (1Y) Largest decline over 1 year	-49.16%	—	—
Max Drawdown (5Y) Largest decline over 5 years	-95.54%	—	—
Current Drawdown Current decline from peak	-59.41%	—	—
Average Drawdown Average peak-to-trough decline	-81.06%	—	—
Ulcer Index Depth and duration of drawdowns from previous peaks	26.40%	—	—

Volatility

Volatility by Period

	MNPR	CDTX	Difference
Volatility (1M) Calculated over the trailing 1-month period	14.39%	—	—
Volatility (6M) Calculated over the trailing 6-month period	48.88%	—	—
Volatility (1Y) Calculated over the trailing 1-year period	87.16%	—	—
Volatility (5Y) Calculated over the trailing 5-year period, annualized	295.98%	—	—
Volatility (10Y) Calculated over the trailing 10-year period, annualized	268.41%	—	—

Financials